Close
What would you like to look for?
Site search

7 June 2022

ImmunOs Therapeutics AG ("ImmunOs"), a Swiss clinical-stage immuno-oncology company, has agreed to a CHF 74 million Series B financing led by incoming co-lead investors Samsara Biocapital, Lightspeed Venture Partners and Gimv, corner-stoned by GL Capital, Mission BioCapital, Peak 6 Strategic Capital and Fiscus Financial, and also joined by existing investors BioMedInvest, Pfizer Ventures and Schroder. In connection with the Series B financing, Marcos Milla (Samsara), Shelley Chu (Lightspeed) and Andreas Jurgeit (Gimv) joined the ImmunOs Board at closing. Proceeds from this financing will enable the Company to pursue its Phase I and II programs in order to explore the full therapeutic potential of IOS-1002.

VISCHER advises ImmunOs on all legal issues related to the transaction. The VISCHER team is led by Christian Wyss (Partner, Corporate/M&A) and Pauline Pfirter (Associate, Corporate/M&A) and includes Nadia Tarolli (Partner, Tax), Marc Prinz (Partner, Employment), Moritz Jäggy (Partner, Immigration), Luzius Zumstein (Senior Associate, Corporate/M&A), Gian Geel (Senior Associate, Employment), Timothy Woodtli (Associate, Corporate/M&A), und Cédric Saladin (Associate, Corporate/M&A).

Categories: Corporate and Commercial, Life Sciences, Pharma, Biotech, Civil Law Notaries, Private Equity & Venture Capital, Startup Desk

Authors

You are currently offline. Some pages or content may fail to load.